A practical reference on investigational status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-04 and is reviewed periodically as new material appears.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Venlafaxine was originally marketed as Effexor in most of the world; generic venlafaxine has been available since around 2008 and extended-release venlafaxine has been available since around 2010. Venlafaxine is sold under many brand names worldwide. In some countries, Effexor is marketed by Viatris after Upjohn was spun off from Pfizer.
=== Distribution === When injected, pentamidine binds to tissues and proteins in the plasma. It accumulates in the kidney, liver, lungs, pancreas, spleen, and adrenal glands. Additionally, pentamidine does not reach curative levels in the cerebrospinal fluid. It has a volume of distribution of 286–1356 liters when given intravenously and 1658–3790 liters when given intramuscularly. Inhaled pentamidine is mainly recovered from the bronchoalveolar lavage fluid of the lungs.
Since its birth as an independent state in 1830, Ecuador had not had a reason to complain against Peru for territorial reasons and they had even signed a friendship and alliance treaty in 1832, but it was only from 1841 when said nation refloated the old Bolivarian claim of Tumbes, Jaén and Maynas. As Minister Charún said in the negotiations of April 1842: "The question of limits existed long before; however, Peru had not received a complaint from Ecuador; beginning to receive them since the enemies of Peru took refuge in that country". José Ballivián, after the War between Peru and Bolivia he executed an anti-Peruvian policy taking advantage of the post-war spirit, however, over time he became unpopular, even the congress refused to declare war again in 1847. Among the actions that executed his government, was to try to conspire against the government of Ramón Castilla, as well as to issue adulterated currency by Bolivia, "el feble", to the detriment of Peruvian merchants in the Altiplano (and benefiting Argentines), in addition to prohibiting exports from Peru. Also, with the help of the Peruvian José Felix Ugayn, he sought to develop a separatist project that sought to annex southern Peru to Bolivia (primarily Moquegua, Tacna, Arica and Tarapacá). Finally, Peruvian-Bolivian relations would stabilize with the Arequipa Treaty of November 1848.
Sources: en.wikipedia.org
MK-2870 or SKB264 is an experimental antibody–drug conjugate. The antibody component is directed against "the trophoblast cell-surface antigen 2 (TROP2), which is overexpressed in many types of solid tumors, coupled to moderate cytotoxic belotecan-derivative through a novel linker which was designed to balance the extracellular stability and intracellular rupture". The drug is developed as a partnership between Merck and the Chinese company Kelun-Biotech.
== Further reading == Technical specifications for selection of essential in vitro diagnostics for SARS-COV-2 (PDF). World Health Organization. 14 June 2021. "Global Action Plan for the Prevention and Control of NCDs 2013-2020". www.who.int.
Phthalimide is the organic compound with the formula C6H4(CO)2NH. It is the imide derivative of phthalic anhydride. It is a sublimable white solid that is slightly soluble in water but more so upon addition of base. It is used as a precursor to other organic compounds as a masked source of ammonia.
Sources: en.wikipedia.org
== Contraindications == The varicella vaccine is not recommended for seriously ill people, pregnant women, people who have tuberculosis, people who have experienced a serious allergic reaction to the varicella vaccine in the past, people who are allergic to gelatin, people allergic to neomycin, people receiving high doses of steroids, people receiving treatment for cancer with x-rays or chemotherapy, as well as people who have received blood products or transfusions during the past five months. Additionally, the varicella vaccine is not recommended for people who are taking salicylates (e.g. aspirin). After receiving the varicella vaccine, the use of salicylates should be avoided for at least six weeks. The varicella vaccine is also not recommended for individuals who have received a live vaccine in the last four weeks, because live vaccines that are administered too soon within one another may not be as effective. It may be usable in people with HIV infections who have a good blood count and are receiving appropriate treatment. Specific antiviral medication, such as acyclovir, famciclovir, or valacyclovir, are not recommended 24 hours before and 14 days after vaccination.
== Brands == Folgers established brand colors, included on their logo, were traditionally a moderately dark red background with white lettering. The white or grey lettering is still used, with a green background signifying decaf and a black background signifying their Noir dark roast. Folgers products available in the United States include:
Phenylketonuria (PKU) is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorders. It may also result in a musty smell and lighter skin. A baby born to a mother who has poorly treated PKU may have heart problems, a small head, and low birth weight. Phenylketonuria is an inherited genetic disorder. It is caused by mutations in the PAH gene, which can result in inefficient or nonfunctional phenylalanine hydroxylase, an enzyme responsible for the metabolism of excess phenylalanine. This results in the buildup of dietary phenylalanine to potentially toxic levels. It is autosomal recessive, meaning that both copies of the gene must be mutated for the condition to develop. The two main types are classic PKU and variant PKU, depending on whether any enzyme function remains. Those with one copy of a mutated gene typically do not have symptoms. Many countries have newborn screening programs for the disease. Treatment is with a diet low in foods that contain phenylalanine and includes special supplements. Babies should use a special formula with a small amount of breast milk. The diet should begin as soon as possible after birth and continue for life. People who are diagnosed early and maintain a strict diet can have normal health and a normal lifespan. Effectiveness is monitored through periodic blood tests. The medication sapropterin dihydrochloride may be useful in some. Phenylketonuria affects about one in 12,000 babies.
On 27 August 2025, President Luiz Inácio Lula da Silva signed Decree No. 12,595/2025, establishing the DTV+ system (also called TV 3.0) as the new standard for Brazilian free-to-air television, based on ATSC 3.0. The standard covers physical, transport, video, audio, subtitles and emergency alert layers. The preparatory phase is expected to be completed in 2025, with the first TV 3.0 transmissions beginning in the first half of 2026 in major capitals. The expansion process to reach coverage across the entire national territory is estimated to take up to 15 years. The system also incorporates internet integration, greater interactivity, accessibility and public services via the television platform. The signing of the decree followed years of studies, research, discussions and debates led by the MCom, involving companies in the sector, academics and specialists. Following the regulation, Brazilian broadcasters may begin implementing the new system. According to the minister of communications, Frederico Siqueira, the signing of the decree marked a historic moment for Brazil, strengthening free-to-air television as a democratic and popular meeting space. He highlighted that TV 3.0 will not change a central principle: free access. The new technology will modernize Brazilian digital television, offering 4K and 8K images, immersive sound, greater interactivity and integration with the internet. The goal is to provide a richer and more personalized experience for viewers, bringing free-to-air television closer to streaming services.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.